that's why i like alkermes.the diabetes drug that only needs to be injected once a week. and a monthly injection that helps treat alcoholism and opiate addiction. and they are in partnership with john & johnson. that helps keep people with severe mental illness on their medication which is hard to do. they are working on an extended release version of abilify. the alkermes version would only have to be injected once a month without making people think they don't need to swallow a pill once or twice a day. rival otsuka is working on a once a month injectable drug that could get fda approval as soon as tomorrow. i'm worried about the competition but the fda approval could be good for them. the company reported a fabulous quarter at the end of january, raised guidance the third time in a row and after spiking up to 23, the stock is below 23. smells like an opportunity to me. let's check in with richard pops. chairman and ceo of alkermes. welcome back. >> good to see you. >> i want to let viewers in the kitchen. i w

chair and ceo of alkermes.ack. >> good to see you. >> i want to let viewers in the kitchen. i was very intrigued by the drug we're talking about, this ch is this drug that you are working on in phase three, the one otsuka is completing against, the antipsychotic. you wanted to make sure that this rival company could be approved tomorrow. >> tomorrow. >> but a lot of literature is about how good the drug is. if someone is coming in against you, why is that a focus? would why would you talk about it? >> two schools of thought. more competition is better. in the u.s., 2% of patients with schizophrenia end up on long acting medications, despite the fact that it's better for them to remember taking their medication each day. >>? spain, that number is 30%. >> 30%. >> the potential for this market to grow -- >> they don't have any money. >> you save money by keeping people out of hospital. >> we are big fans of them getting approved and getting more doctors in medicaid systems that we should use these medicine. right